Therefore, the data generated provide a scientific rationale for co-targeting MEK/PI3K signaling as a strategy for EGFR-TKI resistant NSCLC, especially in K-RAS and PIK3CA mutation in NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.